News

Further exploration of the ethical quandary concerning the Goldwater Rule.

What does recent research tell us about use of nonprescription weight-loss products among teens?

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

Problematic gaming is challenging to treat. Here's how you can get started.

What is new in research on schizophrenia?

Caring adulthood experiences have the power to combat some of the impacts of adverse childhood experiences.

Lacan’s teachings have continued to generate interest and controversy since his death in 1981. Here’s why.

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

If all violence in the US that is due to mental disorders could be eliminated, 95% to 97% of violent behavior would remain.

How does divisive tribalism handicap our efforts to solve the climate emergency?

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

"As we commemorate Black History Month, it is an opportune time to highlight the contributions of Black clinicians while acknowledging past and current shortcomings as well as the imperative to strive for improved equity for clinicians and patients alike."

Explore 10 sides of love in 10 captivating films.

Clinical trial compares outcomes with behavioral activation psychotherapy or antidepressant medication for depression in patients with heart failure.

Available evidence from preclinical studies indicates that semaglutide shows promise for treating Alzheimer disease and Parkinson disease.

One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.

The treatment's PDUFA date is set for August 11, 2024.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

Love: a distraction or inspiration?

"I refuse to see sexual violence as a 'women’s issue.' It is a human issue and should be addressed as one."

How do work and psychiatry evolve and influence each other?

Learn more about the inaugural Black Youth Mental Health Clinical Case Conference Series at Yale Child Study Center, a 6-session event in 2024, that focuses on improving mental health care for Black youth and their families.

Welcome to the Year of the Dragon! What does it mean?

Take a look back at our recent coverage relating to our February content theme.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

What is new in research on bipolar disorder?

New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Football and mental health care: Sometimes predictions work, but it is also worth taking some chances and having backup plans.

New research finds whole-family collaborative care digital mental health interventions help manage disordered eating behaviors in adolescents aged 13-17.